Deals round up – February 26th – March 5th

The week’s announcements began with news from AstraZeneca.

Like Comment

The week’s announcements began with news from AstraZeneca that it is to discontinue development of six of its preclinical autoimmune/anti-inflammatory drugs at its subsidiary MedImmune, but channel them into a new biotech known as Viela Bio. Viela will receive funding of up to $250 million from a consortium of investors that includes Boyu Capital, 6 Dimensions Capital, and Hillhouse Capital. Viela’s most advanced product is now inebilizumab, a CD19-targeted antibody that is currently in phase 2b trials for neuromyelitis optica spectrum disorder.

Following this, Novartis announced that it will team up with Pear Therapeutics in a prescription digital medicine deal targeting schizophrenia and multiple sclerosis. Full details of the deals haven’t been disclosed; however, Novartis is expected to work with Pear on clinical trials to test the responses of a mobile phone app, known as THRIVE, in patients with schizophrenia. Novartis will also work with Pear on a second early-stage program targeting multiple sclerosis.

Finally, Celgene has signed a 4-year deal with Vividion, including an upfront fee of $101 million, to collaborate on identifying potential small-molecule drugs using Vividion’s screening platform. Vividion’s approach, based on research by a team led by Benjamin Cravatt at The Scripps Research Institute, enables the integration of two lead discovery approaches that have proved valuable in identifying small-molecule modulators of challenging targets —phenotypic screening in cells and screening with chemical ‘fragments’. The initial focus of the collaboration will be the ubiquitin–proteasome system, a cellular protein degradation system that is dysfunctional in diseases including cancer and that can also be harnessed to degrade selected proteins with small-molecule compounds

Go to the profile of Raveena Bhambra

Raveena Bhambra

Editor, BioPharma Dealmakers , Nature Research

Hello all, I am the Editor of BioPharma Dealmakers, a quarterly publication that assists companies in identifying potential partners in the pharmaceutical and biotechnology industry and appears in both Nature Biotechnology and Nature Reviews Drug Discovery. I am very passionate about the biopharma industry and have over 15 years of experience of working in the field, specifically in dealmaking, partnering and licensing. In my previous roles I have conducted partner searches identifying both products/technologies and partners for clients, and have edited and written dealmaking-focused reports.

No comments yet.